Physician
Anaheim Urgent Care, INC.
Anaheim Urgent Care, INC. was paid $11.70M by Medicaid between Jan 2018 and Jul 2024, across 63 billing codes. Its largest line is 99204, doctor's office visit, new patient (more involved) — 22% of everything it billed.
33Billing provider infoANAHEIM URGENT CARE, INC.
ANAHEIM, CA 92806
ANAHEIM, CA 92806
33aNPI1962680033assigned 01/31/2008
33bProvider typeFamily Medicine Physician
28Total paid$11.70M
24GClaims593,296
24DCodes billed63
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other Family Medicine Physician providers in California
Rank by total paid#40 of 2,511
Median peer was paid$13K
This provider vs. median911×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,830 | $643K | |
| 2019 | 46,884 | $1.15M | |
| 2020 | 68,885 | $1.09M | |
| 2021 | 162,330 | $2.77M | |
| 2022 | 179,314 | $3.29M | |
| 2023 | 118,023 | $2.76M | |
| 2024incomplete | 30 | $2K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 22% | 52,383 | 52,037 | $2.60M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 70,093 | 65,147 | $2.49M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 14% | 37,231 | 37,072 | $1.58M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 10% | 68,314 | 62,917 | $1.22M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.5% | 42,851 | 40,785 | $997K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 5.1% | 20,787 | 20,344 | $602K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 4.7% | 23,256 | 22,157 | $555K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.9% | 22,185 | 19,910 | $337K |
| 94760 | 2.2% | 63,789 | 59,568 | $259K | |
| 99401 | 1.9% | 61,202 | 57,410 | $220K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.7% | 30,099 | 18,236 | $194K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 12,628 | 11,488 | $128K |
51 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 9,362 | $123K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 18,079 | $102K |
| 99000 | <1% | 25,188 | $56K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 599 | $36K |
| 81003 | <1% | 12,409 | $27K | |
| 99201 | <1% | 454 | $23K | |
| 93000 | <1% | 825 | $18K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,085 | $15K |
| 81025 | <1% | 3,829 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,778 | $12K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 638 | $12K |
| 99205 | Prolong outpt/office vis | <1% | 175 | $11K |
| 99497 | <1% | 266 | $10K | |
| 99051 | <1% | 3,799 | $8K | |
| 36410 | <1% | 1,020 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 924 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 702 | $6K |
| 87807 | <1% | 884 | $5K | |
| S9083 | Global fee urgent care centers | <1% | 698 | $4K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 59 | $3K |
| 69210 | <1% | 119 | $3K | |
| 97597 | <1% | 101 | $2K | |
| 73630 | <1% | 95 | $2K | |
| 99072 | <1% | 1,411 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 334 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 132 | $1K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 16 | $1K |
| 73610 | <1% | 55 | $1K | |
| 90714 | <1% | 40 | $986.46 | |
| 69209 | <1% | 69 | $850.98 | |
| 99173 | <1% | 331 | $748.37 | |
| 86308 | <1% | 180 | $722.04 | |
| 73130 | <1% | 28 | $709.34 | |
| 81002 | <1% | 201 | $662.60 | |
| 73564 | <1% | 24 | $606.60 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 14 | $521.08 |
| 36415 | Collection of venous blood by venipuncture | <1% | 308 | $450.26 |
| 72110 | <1% | 12 | $393.77 | |
| 99406 | <1% | 43 | $374.60 | |
| 99441 | <1% | 210 | $310.98 | |
| 86328 | <1% | 13 | $271.38 | |
| 82962 | <1% | 131 | $194.18 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 80 | $162.87 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30 | $156.52 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24 | $71.00 |
| 85018 | <1% | 32 | $55.50 | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 549 | $25.31 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 26 | $23.04 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 69 | $5.63 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 13 | $5.25 |
| 94761 | <1% | 15 | $1.75 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOLOURIAN, PEJMAN (MEDICAL DIRECTOR)